Johnson & Johnson JNJ

$267.61 +9.83 (3.81%)

Valuation

Market cap
625,031,104,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
23.83
Forward PE
22.83
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
9,712,170
Avg volume
6,844,928
Day's range
$259.04 – $269.67
Shares out
2,409,898,000
Stochastic %K
66%
Beta
0.21
Analysts
Strong Sell
Price target
$282.24

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

USStockDesk Oct 22, 7:11 PM
$SOXL $SOXX Added more in $JNJ and $IBM
0 replies
BigFishEatLittleFish Oct 22, 6:48 PM
$MRNA who’s buying ❓ $MU $AMD $JNJ $NVDA
0 replies
BigFishEatLittleFish Oct 22, 6:42 PM
$JNJ ripping 🚀🚀❗️
0 replies
Outcomes Oct 22, 6:34 PM
$IBRX $MRNA $MRK $PFE $JNJ mRNA BAD.....Covid, flu, cancer....DNA scrambler.
0 replies
USStockDesk Oct 22, 6:24 PM
$SPX is down by 100$ and still both positions are up by 10k in longs in IBM and JNJ $JNJ $IBM $SOXL $SOXX
0 replies
chursinow62 Oct 22, 6:01 PM
$JNJ huge move with more positive headlines coming $300 fast🚀🚀🚀
0 replies
JediInvests Oct 22, 5:28 PM 0 replies
TopOptionAlert Oct 22, 5:18 PM
$JNJ NOV20 275C · still actionable Zone: $265.51 to $269.25 Invalidation: close under $260.77 Objectives: $275.23, then $281.07 The math: up 2.9% to the first objective and 5.1% to the second, against 2.5% risk on the invalidation, about 2 to 1 to the second Dear friend, picture a storm rolling through the chip stocks, down 4 to 8 percent today, and everyone crowding under one solid roof, this old healthcare name. Johnson and Johnson rose about 3.7 percent today to near 267 dollars, back over its 50 day average near 265 dollars, into the shelf it held for most of September. In plain words, buyers are paying for safety while the market shakes, and that rotation is this swing setup. If price holds this shelf, the road runs to 275 dollars first and then the 281 dollar high for the year. A close under 261 dollars says the crowd moved on and the idea is wrong. P.S. Watch the shelf top near 274 dollars, a late September high. A close through it opens the road to 281 dollars.
0 replies